← Back to headlines
Eli Lilly's Market Value Soars Due to Weight-Loss Drugs
American pharmaceutical giant Eli Lilly is projected to reach nearly $140 billion in revenue by 2032, largely driven by its weight-loss medications. The company's stock market valuation has nearly doubled that of Roche and Novartis combined.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
